<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vyne Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/vyne-therapeutics-inc</link>
<description>Latest news and press releases for Vyne Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 17 Dec 2025 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vyne-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d64078dffbe2df121bac.webp</url>
<title>Vyne Therapeutics Inc</title>
<link>https://6ix.com/company/vyne-therapeutics-inc</link>
</image>
<item>
<title>VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-yarrow-bioscience-announce-130000511</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-yarrow-bioscience-announce-130000511</guid>
<pubDate>Wed, 17 Dec 2025 13:00:00 GMT</pubDate>
<description>Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye disease (“TED”)Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being co</description>
</item>
<item>
<title>VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement </title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-and-yarrow-bioscience-announce-merger-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-and-yarrow-bioscience-announce-merger-agreement</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor</description>
</item>
<item>
<title>VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-2025-third-130000553</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-2025-third-130000553</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strategic alternatives12-week, non-clinical toxicology study of VYN202 in dogs to remedy the partial hold in male clinical subjects is ongoing; Company continues to evaluate potential opportunities for VYN202 as a treatment for serious, immune-mediated diseases Cash runway into first half of 2027 based on</description>
</item>
<item>
<title>VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-2025-second-120000029</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-2025-second-120000029</guid>
<pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
<description>Implemented cost reductions extend cash runway into first half of 2027BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today reported financial results as of and for the quarter ended June 30, 2025. The Company is actively evaluating opportunities to enhance</description>
</item>
<item>
<title>VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-topline-results-120000626</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-topline-results-120000626</guid>
<pubDate>Wed, 30 Jul 2025 12:00:00 GMT</pubDate>
<description>Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company Will Terminate Extension Phase of Trial and Seek External Partner for Continued Development of Repibresib BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage bio</description>
</item>
<item>
<title>VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-provides-program-oral-114500595</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-provides-program-oral-114500595</guid>
<pubDate>Wed, 02 Jul 2025 11:45:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today provided a program update for VYN202 following the clinical hold issued by the U.S. Food and Drug Administration (FDA) in April for the Company’s Phase 1b clinical trial in the treatment of moderate-to-s</description>
</item>
<item>
<title>VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-2025-first-120000346</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-2025-first-120000346</guid>
<pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
<description>Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the quarter ended March 31, 2025, and provided a</description>
</item>
<item>
<title>VYNE Therapeutics Provides Update on VYN202 Program</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-provides-vyn202-program-120000199</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-provides-vyn202-program-120000199</guid>
<pubDate>Fri, 25 Apr 2025 12:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that it placed a clinical hold on the Company’s Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis. The clinical hold determination was made following a recent observation of testicular toxicity in dogs from a non-clinical toxicology study with VYN</description>
</item>
<item>
<title>VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-participate-h-c-120000813</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-participate-h-c-120000813</guid>
<pubDate>Thu, 20 Mar 2025 12:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE’s management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday,</description>
</item>
<item>
<title>VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-2024-fourth-130000081</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-2024-fourth-130000081</guid>
<pubDate>Thu, 06 Mar 2025 13:00:00 GMT</pubDate>
<description>Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025Expected cash runway into 2H 2026 BRIDGEWATER, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announ</description>
</item>
<item>
<title>VYNE Therapeutics to Participate in March Investor Conferences</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-participate-march-investor-130000514</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-participate-march-investor-130000514</guid>
<pubDate>Thu, 20 Feb 2025 13:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE’s management will participate in two investor conferences in March. Details are as follows: TD Cowen 45th Annual Health Care Conference, Boston, MAConference Date: March 4, 2025Format</description>
</item>
<item>
<title>VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-initiates-phase-1b-130000510</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-initiates-phase-1b-130000510</guid>
<pubDate>Wed, 19 Feb 2025 13:00:00 GMT</pubDate>
<description>Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designed to provide key insights into VYN202’s potential across a range of chronic, immune-mediated diseases BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated</description>
</item>
<item>
<title>VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-completes-enrollment-in-phase-2b-trial-evaluating-vyn201-for-the-treatment-of-nonsegmental-vitiligo</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-completes-enrollment-in-phase-2b-trial-evaluating-vyn201-for-the-treatment-of-nonsegmental-vitiligo</guid>
<pubDate>Mon, 06 Jan 2025 05:00:00 GMT</pubDate>
<description>Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in</description>
</item>
<item>
<title>VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-positive-top-line-phase-1a-mad-data-for-vyn202-its-novel-bd2-selective-bet-inhibitor</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-positive-top-line-phase-1a-mad-data-for-vyn202-its-novel-bd2-selective-bet-inhibitor</guid>
<pubDate>Mon, 23 Dec 2024 05:00:00 GMT</pubDate>
<description>Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD</description>
</item>
<item>
<title>VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported</description>
</item>
<item>
<title>VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-positive-phase-1a-sad-data-for-vyn202-a-novel-bd2-selective-bet-inhibitor</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-positive-phase-1a-sad-data-for-vyn202-a-novel-bd2-selective-bet-inhibitor</guid>
<pubDate>Thu, 12 Sep 2024 04:00:00 GMT</pubDate>
<description>VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood</description>
</item>
<item>
<title>VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 14 Aug 2024 04:00:00 GMT</pubDate>
<description>Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202 progressing, with data</description>
</item>
<item>
<title>VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-granting-of-composition-of-matter-patent-for-vyn202-a-novel-bd2-selective-bet-inhibitor</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-granting-of-composition-of-matter-patent-for-vyn202-a-novel-bd2-selective-bet-inhibitor</guid>
<pubDate>Tue, 16 Jul 2024 04:00:00 GMT</pubDate>
<description>BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-appointment-of-subhashis-banerjee-md-as-senior-vice-president-of-clinical-development</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-appointment-of-subhashis-banerjee-md-as-senior-vice-president-of-clinical-development</guid>
<pubDate>Tue, 09 Jul 2024 04:00:00 GMT</pubDate>
<description>Dr. Banerjee previously served as Vice President & Disease Area Head, Rheumatology and Dermatology at Bristol Myers Squibb BRIDGEWATER, N.J., July 09, 2024</description>
</item>
<item>
<title>VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202</title>
<link>https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-dosing-of-first-participants-in-phase-1a-trial-of-novel-bd2-selective-bet-inhibitor-vyn202</link>
<guid isPermaLink="true">https://6ix.com/company/vyne-therapeutics-inc/news/vyne-therapeutics-announces-dosing-of-first-participants-in-phase-1a-trial-of-novel-bd2-selective-bet-inhibitor-vyn202</guid>
<pubDate>Thu, 13 Jun 2024 04:00:00 GMT</pubDate>
<description>VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics</description>
</item>
</channel>
</rss>